Research Appraisalobservational

Transcriptomic Analysis and Multiple Machine Learning Approaches Identify ZDHHC20 and Its Highly Correlated Gene AK5 as Biomarkers in Multiple System Atrophy

Journal of molecular neuroscience : MNLu, Zhipeng, Li, Zhongqi, Yin, Zhibiao et al.16 May 2026DOI

Clinical Snapshot

75CEBM
Evidence: Moderateobservational

PICO Framework

P — PopulationPostmortem brain tissues from patients with multiple system atrophy (MSA) and healthy controls
I — InterventionTranscriptomic analysis using bulk and single-nucleus RNA sequencing
C — ComparatorHealthy control brain tissues
O — OutcomesIdentification of ZDHHC20 and AK5 as potential biomarkers; gene expression patterns in oligodendrocytes; functional pathways related to mitochondrial dysfunction

Bottom Line

This transcriptomic study identifies ZDHHC20 and AK5 as potential biomarkers for multiple system atrophy, showing significant downregulation particularly in cerebellar white matter oligodendrocytes. The research employed sophisticated bioinformatics approaches including multiple machine learning algorithms and single-cell analysis. However, the clinical utility remains limited as the findings are based on postmortem tissue analysis. Key limitations include insufficient detail about sample characteristics, lack of confounding variable adjustment, and unclear generalisability beyond the study population. While the biological insights regarding mitochondrial dysfunction and energy metabolism pathways are valuable, translation to clinical practice would require development of ante-mortem biomarker assays and validation in diverse populations including Australian patients. The study represents important foundational research but requires substantial additional work before clinical implementation.

Evidence: Moderate

Key Findings

  • P Value: Not specified

  • Effect Size: Significant downregulation (specific magnitude not reported in abstract)

  • Primary Outcome: ZDHHC20 and AK5 identified as significantly downregulated genes in MSA brain tissue

  • Nnt Or Sensitivity: Biomarker sensitivity and specificity not reported

  • Confidence Interval: Not reported

Clinical Application

Limited - requires postmortem tissue analysis or development of ante-mortem biomarker assays Relevant to Australian neurologists managing MSA patients; would require validation in Australian cohorts before clinical implementation Patients with suspected multiple system atrophy requiring diagnostic confirmation

Abstract

Multiple system atrophy (MSA) is a fatal neurodegenerative disorder lacking effective diagnostic tools. While protein palmitoylation is crucial for neuronal function, its specific role in MSA pathogenesis remains unexplored. We integrated bulk and single-nucleus RNA sequencing (snRNA-seq) data from postmortem MSA brain tissues. Eight machine learning algorithms were utilized to screen palmitoylation-related genes. Downstream analyses, including functional enrichment, cellular deconvolution, and pseudotime trajectory inference, were then conducted. ZDHHC20 and its highly correlated gene, AK5, were identified as hub genes. Both demonstrated significant downregulation in MSA, particularly within the cerebellar white matter. Functional enrichment analysis linked this expression pattern to mitochondrial dysfunction and impaired energy metabolism. Furthermore, snRNA-seq revealed that ZDHHC20 and AK5 are predominantly expressed in oligodendrocytes and exhibit lower expression levels along the developmental trajectory in MSA compared to healthy controls. ZDHHC20 and AK5 represent promising biomarkers for MSA. These findings provide new insights into the diagnosis and treatment of MSA.

References

  1. 1.Lu, Z., Li, Z., Yin, Z., Liu, J., & Fang, P. (2026). Transcriptomic analysis and multiple machine learning approaches identify ZDHHC20 and its highly correlated gene AK5 as biomarkers in multiple system atrophy. Journal of Molecular Neuroscience. https://doi.org/10.1038/s41467-024-49105-3
Share:XLinkedIn

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service